Tilray Brands (TLRY) Free Cash Flow (2017 - 2026)
Tilray Brands (TLRY) posted Free Cash Flow of -$21.9 million for Q1 2026, down 157.02% on a QoQ basis from -$8.5 million in Q4 2025, and down 8.76% year-over-year from -$24.0 million in Q1 2025.
Tilray Brands (TLRY) Free Cash Flow (2017 - 2026) Analysis & Trends
Tilray Brands' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$21.9 million for Q1 2026.
- Quarterly Free Cash Flow fell 8.76% year-over-year to -$21.9 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$51.0 million (up 41.68% YoY) and the FY2025 annual result came in at -$127.5 million, down 111.98% from the prior year.
- Free Cash Flow was -$21.9 million for Q1 2026 at Tilray Brands, down from -$8.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $31.2 million in Q2 2023 and bottomed at -$51.0 million in Q1 2022.
- A 5-year average of -$18.2 million and a median of -$20.2 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 890.02% — and 2023, when it jumped 219.43%.
- Tilray Brands' Free Cash Flow stood at $24.7 million in 2022, then sank by 247.0% to -$36.3 million in 2023, then dropped by 27.27% to -$46.2 million in 2024, then jumped by 81.51% to -$8.5 million in 2025, then plunged by 157.02% to -$21.9 million in 2026.
- Business Quant data shows TLRY's Free Cash Flow at -$21.9 million in Q1 2026, -$8.5 million in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | -21.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -21.94 Mn |
| Feb 28, 2026 | -21.94 Mn |
| Nov 30, 2025 | -8.54 Mn |
| Nov 30, 2025 | -8.54 Mn |
| Aug 31, 2025 | -1.34 Mn |
| Aug 31, 2025 | -1.34 Mn |
| May 31, 2025 | -19.14 Mn |
| May 31, 2025 | -19.14 Mn |
| Feb 28, 2025 | -20.18 Mn |
| Feb 28, 2025 | -20.18 Mn |
| Nov 30, 2024 | -46.16 Mn |
| Nov 30, 2024 | -46.16 Mn |
| Aug 31, 2024 | -42.04 Mn |
| Aug 31, 2024 | -42.04 Mn |
| May 31, 2024 | 21.00 Mn |
| May 31, 2024 | 21.00 Mn |
| Feb 29, 2024 | -24.89 Mn |
| Feb 29, 2024 | -24.89 Mn |
| Nov 30, 2023 | -36.27 Mn |
| Nov 30, 2023 | -36.27 Mn |